| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HepaCAM2 |
| Uniprot No | A8MVW5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-351aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSLKVTVPS HTVHGVRGQA LYLPVHYGFH TPASDIQIIW LFERPHTMPK YLLGSVNKSV VPDLEYQHKF TMMPPNASLL INPLQFPDEG NYIVKVNIQG NGTLSASQKI QVTVDDPVTK PVVQIHPPSG AVEYVGNMTL TCHVEGGTRL AYQWLKNGRP VHTSSTYSFS PQNNTLHIAP VTKEDIGNYS CLVRNPVSEM ESDIIMPIIY YGPYGLQVNS DKGLKVGEVF TVDLGEAILF DCSADSHPPN TYSWIRRTDN TTYIIKHGPR LEVASEKVAQ KTMDYVCCAY NNITGRQDET HFTVIITSVG LEKLAQKGKS LSP |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于HepaCAM2重组蛋白的公开研究文献目前较为有限，以下为基于相关领域研究的假设性示例(请注意这些文献为虚构，仅作格式参考)：
---
1. **文献名称**: *Recombinant HepaCAM2 Protein Inhibits Tumor Growth via ERK Signaling Pathway*
**作者**: Zhang, L. et al.
**摘要**: 本研究在大肠杆菌系统中成功表达并纯化了HepaCAM2重组蛋白，发现其通过抑制ERK磷酸化通路显著降低肝癌细胞增殖，提示其在肿瘤治疗中的潜在应用。
2. **文献名称**: *Structural Characterization of HepaCAM2 Recombinant Protein Expressed in HEK293 Cells*
**作者**: Li, X. & Wang, Y.
**摘要**: 作者利用哺乳动物表达系统获得高纯度HepaCAM2重组蛋白，通过质谱和晶体学分析揭示其胞外结构域的关键功能区域，为后续机制研究提供结构基础。
3. **文献名称**: *HepaCAM2 Recombinant Protein Modulates Cell-Cell Adhesion in Renal Tubular Epithelium*
**作者**: Chen, R. et al.
**摘要**: 实验证明HepaCAM2重组蛋白可增强肾小管上皮细胞的黏附连接，并通过调控E-cadherin表达抑制EMT过程，提示其在慢性肾病中的保护作用。
---
**建议**：实际研究中请通过**PubMed**或**Web of Science**以关键词“HepaCAM2 recombinant”检索最新文献，或关注相关基因家族(如HepaCAM/CCM2)的研究进展。部分真实研究可能涉及“HepaCAM”(非HepaCAM2)，需注意命名差异。
HepaCAM2. a member of the hepatocyte cell adhesion molecule (HepaCAM) family, is a transmembrane protein implicated in cell-cell adhesion, signaling, and tumor suppression. Structurally, it shares conserved features with HepaCAM, including an extracellular immunoglobulin (Ig)-like domain, a single-pass transmembrane region, and a cytoplasmic tail that may interact with intracellular signaling partners. HepaCAM2 is predominantly expressed in epithelial tissues, particularly in the liver, kidneys, and bladder, where it regulates cellular processes such as proliferation, differentiation, and apoptosis. Its adhesive properties are mediated through homophilic or heterophilic interactions, potentially stabilizing tissue architecture and maintaining polarity.
Research highlights its role as a putative tumor suppressor. Downregulation or loss of HepaCAM2 has been observed in multiple cancers, including hepatocellular carcinoma (HCC) and bladder cancer, often correlating with poor prognosis. Epigenetic silencing via promoter hypermethylation or post-translational modifications may contribute to its reduced expression in malignancies. Functionally, HepaCAM2 is thought to inhibit oncogenic pathways (e.g., Wnt/β-catenin) while promoting pro-apoptotic signals, though its precise mechanisms remain under investigation.
Recombinant HepaCAM2 protein, produced via bacterial or mammalian expression systems, serves as a critical tool for studying its biological roles. Purified forms are utilized in vitro to explore binding partners, signaling cascades, and therapeutic potential. Recent studies suggest that restoring HepaCAM2 expression or administering its recombinant form could suppress tumor growth or enhance chemotherapy sensitivity, positioning it as a candidate for targeted cancer therapies. Further research is needed to clarify its tissue-specific functions and clinical applicability.
×
